Corona Remedies made a healthy stock market debut to list at more than 38 percent premium over its initial public offering (IPO) price on the National Stock Exchange (NSE), following a massive subscription of 137.04 times between December 8-10 in the primary market.
- Silver Rally Ahead? Neal Bhai Sees ₹2,40,000–₹2,50,000 Lakh Target Soon
- Silver Price Breakout: Big Move Begins — No More Silent Signals
- WTI Crude Oil Price Forecast: Bearish Trend Keeps WTI Below $60 – Market Under Pressure
- Fed Meeting Live: US Federal Reserve Likely to Cut Interest Rates for 3rd Time This Year, 2026 Outlook Key
- MCX Silver Price Surges Above ₹2 Lakh on MCX – Will Rally Continue? Analysts Share Outlook
Shares of Corona Remedies were listed at Rs 1,470 per share on the NSE, a decent premium of 38.42 percent. The Rs 655.37-crore issue had a price band of Rs 1,008-1,062 per share.
On the BSE, the shares of the company were listed at Rs 1,452 per share, a premium of 36.72 percent. The company’s market capitalization post listing of shares stood at Rs 8,880.44 crore.
Corona Remedies IPO share market debut was better than the expectations in the grey market, which had expected a 32 percent listing gains. Earleir, the issue mobilised Rs 195 crore from anchor investors.
Shivani Nyati, Head of Wealth at Swastika Investmart, suggested short-term investors may consider booking partial profits, while long-term investors could hold the remainder given the company’s steady performance and presence in chronic therapy segments.
Headquartered in Ahmedabad, Corona Remedies is a pharmaceutical formulation company engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabeto, pain management, urology and other therapeutic areas.
Its diversified product portfolio comprises 67 brands catering to a range of therapeutic areas as of December 2024.
Disclaimer
This article is intended for educational purposes only. The views and opinions expressed are those of individual analysts or brokerage firms and do not represent the views of GoldSilverReports.com. Investors are strongly advised to consult certified financial experts before making any investment or trading decisions.
| Follow us on |
| Telegram, Whatsapp , Facebook, Twitter, Instagram, YouTube, Google Business Profile and Truth Social. |